1. Home
  2. TXG vs NVAX Comparison

TXG vs NVAX Comparison

Compare TXG & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TXG
  • NVAX
  • Stock Information
  • Founded
  • TXG 2012
  • NVAX 1987
  • Country
  • TXG United States
  • NVAX United States
  • Employees
  • TXG N/A
  • NVAX N/A
  • Industry
  • TXG Biotechnology: Laboratory Analytical Instruments
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TXG Industrials
  • NVAX Health Care
  • Exchange
  • TXG Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • TXG 1.3B
  • NVAX 1.3B
  • IPO Year
  • TXG 2019
  • NVAX 1995
  • Fundamental
  • Price
  • TXG $14.11
  • NVAX $7.47
  • Analyst Decision
  • TXG Buy
  • NVAX Buy
  • Analyst Count
  • TXG 12
  • NVAX 6
  • Target Price
  • TXG $14.13
  • NVAX $15.33
  • AVG Volume (30 Days)
  • TXG 3.7M
  • NVAX 5.0M
  • Earning Date
  • TXG 08-07-2025
  • NVAX 08-07-2025
  • Dividend Yield
  • TXG N/A
  • NVAX N/A
  • EPS Growth
  • TXG N/A
  • NVAX N/A
  • EPS
  • TXG N/A
  • NVAX 2.97
  • Revenue
  • TXG $624,662,000.00
  • NVAX $1,254,962,000.00
  • Revenue This Year
  • TXG N/A
  • NVAX $55.39
  • Revenue Next Year
  • TXG $5.69
  • NVAX N/A
  • P/E Ratio
  • TXG N/A
  • NVAX $2.51
  • Revenue Growth
  • TXG N/A
  • NVAX 25.92
  • 52 Week Low
  • TXG $6.78
  • NVAX $5.01
  • 52 Week High
  • TXG $24.76
  • NVAX $17.81
  • Technical
  • Relative Strength Index (RSI)
  • TXG 68.91
  • NVAX 59.44
  • Support Level
  • TXG $11.45
  • NVAX $6.93
  • Resistance Level
  • TXG $14.16
  • NVAX $8.46
  • Average True Range (ATR)
  • TXG 0.71
  • NVAX 0.34
  • MACD
  • TXG 0.08
  • NVAX 0.08
  • Stochastic Oscillator
  • TXG 93.01
  • NVAX 45.90

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: